Potential Application Beyond Weight Loss There is some therapeutic potential for GLP-1 receptor agonists beyond weight loss, with early research showing promising implications for treating various metabolic and cardiovascular conditions
The metabolic improvements and weight loss achieved with incretin-based therapies are associated with improved fertility
Although direct clinical evidence of systemic NAD(P) depletion during GLP-1RA therapy is lacking, experimental and observational studies suggest that NAD turnover and micronutrient status can be altered in obesity and inflammatory states [83, 85], supporting the biological plausibility of substrate-sensitive vulnerability
( B ) Quantification of glycolysis, glycolytic capacity, and glycolytic reserves in caSMCs pretreated with 100 nM GLP-1(2836) or scrambled control for 20 minutes
Instead, gently swirl the vial or roll it between your palms
This overview is informational and does not replace official prescribing information or individualized medical advice